These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36420955)

  • 1. Continuation of depot olanzapine pamoate after post-injection delirium/sedation syndrome (PDSS) in a case of bipolar mania-a clinical conundrum.
    Kumar B S; Sudheer N; Chichra A; George DE
    Bipolar Disord; 2023 Mar; 25(2):167-169. PubMed ID: 36420955
    [No Abstract]   [Full Text] [Related]  

  • 2. Case series profile of olanzapine post-injection delirium/sedation syndrome.
    Seebaluck J; Downes MA; Brown J; Harris K; Isoardi KZ; Chan BS
    Br J Clin Pharmacol; 2023 Feb; 89(2):903-907. PubMed ID: 36349832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
    McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
    BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine: a review of rapid and long-acting parenteral formulations.
    Owen RT
    Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.
    Luedecke D; Schöttle D; Karow A; Lambert M; Naber D
    CNS Drugs; 2015 Jan; 29(1):41-6. PubMed ID: 25424243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?
    Łukasik-Głębocka M; Sommerfeld K; Teżyk A; Panieński P; Żaba C; Zielińska-Psuja B
    Basic Clin Pharmacol Toxicol; 2015 Sep; 117(3):213-4. PubMed ID: 25703610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
    Novakovic V; Adel T; Peselow E; Lindenmayer JP
    Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.
    Venkatesan V; Khanra S; Mandal K; Deepak MB
    Clin Neuropharmacol; 2019; 42(2):64-65. PubMed ID: 30747749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Mohammad M; Alaoui-Ismaili Z; Baandrup L; Barzanji AF
    Ugeskr Laeger; 2023 May; 185(19):. PubMed ID: 37170738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Jan; 63(1):140-50. PubMed ID: 18834452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].
    Buts K; Van Hecke J
    Tijdschr Psychiatr; 2014; 56(4):273-6. PubMed ID: 24807388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.
    Keck PE; Corya SA; Altshuler LL; Ketter TA; McElroy SL; Case M; Briggs SD; Tohen M
    J Clin Psychiatry; 2005 May; 66(5):611-6. PubMed ID: 15889948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.
    Revicki DA; Paramore LC; Sommerville KW; Swann AC; Zajecka JM;
    J Clin Psychiatry; 2003 Mar; 64(3):288-94. PubMed ID: 12716270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.
    Meehan K; Zhang F; David S; Tohen M; Janicak P; Small J; Koch M; Rizk R; Walker D; Tran P; Breier A
    J Clin Psychopharmacol; 2001 Aug; 21(4):389-97. PubMed ID: 11476123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.
    Bushe CJ; Falk D; Anand E; Casillas M; Perrin E; Chhabra-Khanna R; Detke HC
    BMC Psychiatry; 2015 Apr; 15():65. PubMed ID: 25886006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania.
    Chengappa KN; Baker RW; Shao L; Yatham LN; Tohen M; Gershon S; Kupfer DJ
    Bipolar Disord; 2003 Feb; 5(1):1-5. PubMed ID: 12656931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
    Bridle C; Palmer S; Bagnall AM; Darba J; Duffy S; Sculpher M; Riemsma R
    Health Technol Assess; 2004 May; 8(19):iii-iv, 1-187. PubMed ID: 15147609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.
    Suppes T; Brown E; Schuh LM; Baker RW; Tohen M
    J Affect Disord; 2005 Dec; 89(1-3):69-77. PubMed ID: 16253344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.
    Vieta E; Panicali F; Goetz I; Reed C; Comes M; Tohen M;
    J Affect Disord; 2008 Feb; 106(1-2):63-72. PubMed ID: 17582508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.